FIELD: biotechnology.
SUBSTANCE: what is presented is a method for preparing T-cell(s) for immunotherapy in cancer treatment, involving genetic modification of said T-cell(s) by inactivating a gene coding an immune control point protein, and a gene which codes a T cell receptor (TCR) component; and introduction into T-cells of nucleic acid coding chimeric antigenic receptor directed against antigen associated with tumor. Also disclosed are: recovered T-cell or cell line obtained by said method; a pharmaceutical composition for treating cancer and a method of treating a patient.
EFFECT: this group of inventions can find application in adaptive therapy of cancer.
24 cl, 31 dwg, 15 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR CONSTRUCTING HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2725542C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR IMPROVED IMMUNE CELL THERAPY | 2018 |
|
RU2797304C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF ENDONUCLEASE CBLB | 2018 |
|
RU2779097C2 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
